TrialArthritis and rheumatism2011

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Richard Furie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.